期刊文献+

关于疫苗分类管理的回顾分析 被引量:3

Retrospective Analysis on Classified Administration of Vaccine
暂未订购
导出
摘要 目的:针对目前疫苗管理中出现的新情况、新问题提出对策。方法:结合相关法规,分析目前我国疫苗管理中存在的问题。结果与结论:我国要全面实行疫苗分类管理,必须尽快走上法制化轨道,完善疫苗分类管理制度,强化部门监管职能,采取监、帮、促相结合的管理手段,以及建立相应的补偿机制。 OBJECTIVE:To propose countermeasures aimed at the new situation and problems arose from the current administration on vaccine. METHODS: Combining the related codes, problems in the current administration on vaccine were an alyzed. RESULTS & CONCLUSION :To implement overall classified administration on vaccine in China, the legal track should be followed as soon as possible; the classified vaccine administration system should be improved; departments' functional, authority of supervision should be strengthcned;thc combined administration means of supervising,assisting and promoting should be adopted and the corresponding compensation mechanism should be established.
出处 《中国药房》 CAS CSCD 北大核心 2006年第4期292-293,共2页 China Pharmacy
关键词 疫苗 分类管理 对篆 Vaccine Classified administration Countermeasures
  • 相关文献

参考文献3

  • 1中华人民共和国卫生部.疫苗流通和预防接种管理条例[S]国务院令[2005]第434号[Z].,..
  • 2中华人民共和国卫生部.中华人民共和国传染病防治法实施办法[S]卫生部令[1991]第17号[Z].,..
  • 3中华人民共和国卫生部.预防用生物制品生产供应管理办法[S]卫生部令[1994]第37号[Z].,..

同被引文献20

  • 1李娟,杨雨生.《疫苗流通和预防接种管理条例》之管窥[J].微生物学免疫学进展,2005,33(3):97-98. 被引量:7
  • 2时延申,张卫,曹洪生.关于对当前二类疫苗流通监管现状的思考[J].中国卫生法制,2007,15(3):16-17. 被引量:4
  • 3范晨阳,马彦,孙美平,付建平,王文胜,王秀娟.疾病预防控制中心疫苗管理模式探讨[J].中国公共卫生,2007,23(8):998-999. 被引量:11
  • 4von Gabain A, Nagy E, Decker T. Novel paradigms in vaccine development: from small pox eradication to therapeutic vaccines [J]. Biol Chem, 2008, 389 (5): 455-456.
  • 5Zhu FC, Wang H, Fang HH, et al. A Novel Influenza A(H1N1) Vaccine in Various Age Groups[J].Engl J Med, 2009, 361 (25): 2414-2423.
  • 6Leslie M. Immunology. Flu antibodies stir new hope for treatment I-J]. Vaccine Science, 2009,323 (5918): 1160.
  • 7Okeke IN. Cholera vaccine will reduce antibiotic use[J].Science, 2009, 325 (5941) : 674.
  • 8Stebbing J, Wood C, Atkins M, et al. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments [J].Cancer, 2008, 112 (5) : 955-961.
  • 9Carniel EF, Morcillo AM, Blotta MH, et al. Immunogenicity and safety of combined intradermal recombinant Hepatitis B with BCG vaccines at birth[J]. Vaccine, 2008, 26(5) : 647-652.
  • 10Mizukami T, Masumi A, Momose H, et al. An improved abnormal toxicity test by using reference vaccine-specific body weight curves and histopathological data for monitoring vaccine quality and safety in Japan[J]. Biologicals, 2009, 37 ( 1 ) : 8-17.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部